If you're researching stem cell therapy, you've probably encountered two kinds of websites: ones that promise miraculous healing for everything from arthritis to Alzheimer's, and ones that dismiss the entire field as unproven hype. The truth, as usual, lives in between.
This article is an honest broker. We've broken down the major conditions treated with stem cell therapy and assessed the realistic outcome range for each — based on published clinical evidence, not marketing claims. Where the evidence is strong, we'll say so. Where it's weak or preliminary, we'll say that too.
How to Read This Guide
For each condition, we provide the evidence level (L1–L4), the approximate response rate (percentage of patients reporting meaningful improvement), a realistic outcome range, and what "improvement" typically looks like. These are ranges, not promises. Your individual outcome depends on factors including disease severity, age, overall health, cell source, and adherence to post-treatment protocols.
Condition-by-Condition Breakdown
Knee Osteoarthritis
L1 · RCT L2 · CohortThe strongest evidence base in stem cell therapy. Multiple RCTs and large cohort studies have evaluated MSC injection for knee OA, primarily Kellgren-Lawrence grades II–III (moderate degeneration).
Realistic outcomes: 70–85% of patients report meaningful pain reduction and functional improvement at 12 months. WOMAC pain scores typically improve by 40–60%. MRI evidence of cartilage preservation (slowed degeneration) is documented in some studies. Improvement typically peaks at 6–12 months and can persist for 2–3+ years.
What "improvement" means here: Less pain walking and climbing stairs, reduced need for pain medication, delayed or avoided knee replacement, return to moderate recreational activity. It does not mean cartilage is regrown to its original state.
Who responds less well: Advanced OA (grade IV), patients over 75, those with significant mechanical deformity (varus/valgus malalignment), and patients with BMI over 35.
Shoulder (Rotator Cuff & OA)
L2 · CohortSolid cohort evidence, especially for partial-thickness rotator cuff tears. MSC therapy is increasingly used as an alternative to surgical repair for partial tears and as an adjunct for post-surgical healing.
Realistic outcomes: 65–80% of patients with partial rotator cuff tears report improved function and pain at 12 months. Outcomes for full-thickness tears are less predictable. Shoulder OA responds similarly to knee OA but with less published data.
What "improvement" means here: Better overhead reach, reduced night pain, return to activities like swimming or tennis. Some patients avoid surgery; others use MSC therapy to optimize post-surgical healing.
Hip Osteoarthritis
L2 · CohortGrowing evidence, but less data than knee OA. The hip joint's depth and anatomy make it technically more challenging to treat, but cohort studies show promising results for early-to-moderate hip OA.
Realistic outcomes: 60–75% of patients report meaningful improvement at 12 months. Harris Hip Scores typically improve by 30–50%. Results are best for patients with early degeneration who want to delay hip replacement.
Important caveat: For advanced hip OA with bone-on-bone contact, stem cell therapy is unlikely to reverse the damage. Total hip replacement remains the standard of care for end-stage hip disease. MSC therapy is most valuable as a bridge or delay strategy for patients who aren't yet ready for replacement.
Spine (Disc Degeneration & Facet Arthropathy)
L2 L3Moderate evidence for discogenic pain; weaker for other spinal conditions. Intradiscal MSC injection for degenerative disc disease is being actively studied, with some encouraging results for patients with mild-to-moderate disc degeneration and preserved disc height.
Realistic outcomes: 50–65% of patients report meaningful pain reduction at 12 months. Results are highly variable depending on the specific spinal pathology. Facet joint arthropathy may respond better than disc degeneration in some cases.
Honest assessment: Spinal conditions are complex and multifactorial. The spine has lower blood supply than peripheral joints, which may affect MSC viability and outcomes. Patient selection is especially critical here — not every spinal pain patient is a good candidate for stem cell therapy.
Autoimmune Conditions (RA, Lupus, MS)
L3 · Case SeriesInvestigational. MSCs have documented immunomodulatory properties — they can downregulate overactive immune responses. This has generated significant interest in their potential for autoimmune conditions. However, clinical evidence is limited to case series and small uncontrolled studies.
Realistic outcomes: Variable. Some patients in case series report symptom improvement; others show no change. Without controlled trials, it's impossible to separate treatment effects from placebo effects or natural disease fluctuation. Response rates of 30–50% are cited in case series, but these numbers should be interpreted cautiously.
What patients should know: Autoimmune conditions are chronic and complex. Stem cell therapy should be considered as a potential complement to conventional immunosuppressive therapy, not a replacement for it. Any clinic claiming to "cure" autoimmune disease with stem cells should be viewed with extreme skepticism.
Neurological Conditions (Stroke, TBI, Parkinson's, ALS)
L3 L4 · PreclinicalInvestigational. The blood-brain barrier, the complexity of neural circuitry, and the limited regenerative capacity of the central nervous system make neurological conditions among the most challenging targets for stem cell therapy. Preclinical research is active; clinical translation is early.
Realistic outcomes: Insufficient controlled human data to provide reliable outcome ranges. Case series report individual improvement stories, but systematic evaluation is lacking. Larger clinical trials are underway for stroke and spinal cord injury specifically.
What patients should know: This is the frontier of regenerative medicine. Patients considering stem cell therapy for neurological conditions should seek treatment through clinical trials or at academic institutions with published research protocols. Be wary of any clinic offering guaranteed outcomes for neurological conditions — the science isn't there yet.
Factors That Influence Your Personal Outcome
Regardless of condition, several factors consistently predict better stem cell therapy outcomes: earlier intervention (less severe degeneration at the time of treatment), younger biological age (though patients into their 70s can respond well), lower BMI (obesity increases joint stress and inflammatory load), commitment to post-treatment rehabilitation, and choosing a provider with standardized protocols and outcome tracking.
Conversely, factors associated with poorer outcomes include advanced disease (bone-on-bone contact, complete tissue loss), systemic inflammation (uncontrolled diabetes, smoking), unrealistic expectations (expecting a "cure" rather than meaningful improvement), and lack of post-treatment rehabilitation.
Want an Honest Assessment for Your Condition?
Tell us about your specific situation and we'll provide a straightforward evaluation of whether stem cell therapy in Colombia is likely to help — and what realistic improvement might look like.
Request Your Assessment →